First Trust NASDAQ Technology Dividend Index Fund (NASDAQ: TDIV)

First Trust NASDAQ Technology Dividend Index Fund (NASDAQ:TDIV), Trade Ideas

First Trust NASDAQ Technology Dividend Index Fund

Goldman Sachs analyst Toshiya Hari maintains Seagate Tech Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STX#NASDAQ">STX</a>) with a Neutral and raises the price target from $84 to $96.

News

Price Target

Analyst Ratings

Goldman Sachs Maintains Neutral on Seagate Tech Hldgs, Raises Price Target to $96

Marti increases June 30, 2024 unique rider target from 850,000 to 900,000, and maintains 155,000 registered driver target

Marti's Ride-Hailing Service Reaches Over 788,000 Riders And Over 145,000 Registered Drivers

Goldman Sachs analyst Jordan Alliger maintains Ryder System (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/R#NYSE">R</a>) with a Buy and raises the price target from $122 to $135.

Goldman Sachs Maintains Buy on Ryder System, Raises Price Target to $135

<a href="https://www.bms.com/assets/bms/us/en-us/pdf/investor-info/doc_financials/quarterly_reports/2024/Preliminary-Q1-2024-Acquired-IPRD-and-Licensing-Income-Schedule.pdf">https://www.bms.com/assets/bms/us/en-us/pdf/investor-info/doc_financials/quarterly_reports/2024/Preliminary-Q1-2024-Acquired-IPRD-and-Licensing-Income-Schedule.pdf</a>
&nbsp;

Guidance

Bristol-Myers Discloses Prelim. $6.29 GAAP & Non-GAAP EPS Impact For 3 Months Ended March 31 Related To Acquired IPRD & Licensing Income

Goldman Sachs analyst George Tong maintains MSCI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSCI#NYSE">MSCI</a>) with a Neutral and lowers the price target from $615 to $526.

MSCI

Goldman Sachs Maintains Neutral on MSCI, Lowers Price Target to $526

Amesite Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMST#NASDAQ">AMST</a>) shares&nbsp;are&nbsp;skyrocketing&nbsp;after&nbsp;the company launched the beta version of&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/04/g38400516/amesite-launches-revolutionary-nursemagic-app-in-beta-to-empower-5-2-million-nurses-with-ai-tools" rel="noreferrer noopener">NurseMagic</a><a target="_blank" href="https://www.benzinga.com/pressreleases/24/04/g38400516/amesite-launches-revolutionary-nursemagic-app-in-beta-to-empower-5-2-million-nurses-with-ai-tools" rel="noreferrer noopener">, an application designed for nurses</a>.
The new web app uses AI to provide helpful and easy-to-use tools for over 5.2 million nurses, making their daily tasks&nbsp;easier&nbsp;and more efficient.&nbsp;
The platform also offers accredited continuing education (CE) programs to nurses on the app, enabling them to meet&nbsp;requirements&nbsp;for licensure.
Some of the&nbsp;features of the app&nbsp;include translating medical terms into simple language, creating quick work emails, offering information about medications&nbsp;and&nbsp;enabling nurses to explain medical practices to patients.
&#8220;We want to equip every nurse on the planet with tools that deliver immediate, qualified information, and address the demands on their time while leveraging their expertise,&#8221; said CEO Ann Marie Sastry.
The company also plans to add more features and bring more announcements.
Amesite, an education tech SaaS company, offers its proprietary learning platform and content services to deploy affordable and effective AI for white-labeled online learning programs for colleges and universities.&nbsp;
Price Action: AMST shares are trading higher by 102% at $4.04 at the last check Wednesday.
Photo via Shutterstock

Equities

Movers

General

AMST

Why Edtech Company Amesite Shares Are Skyrocketing Today

Maxim Group analyst Matthew Galinko initiates coverage on Lakeland Industries (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LAKE#NASDAQ">LAKE</a>) with a Buy rating and announces Price Target of $22.

Initiation

LAKE

Maxim Group Initiates Coverage On Lakeland Industries with Buy Rating, Announces Price Target of $22

Goldman Sachs analyst Jason English maintains Kimberly-Clark (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMB#NYSE">KMB</a>) with a Buy and raises the price target from $135 to $152.

Goldman Sachs Maintains Buy on Kimberly-Clark, Raises Price Target to $152

On Wednesday, U.S. Secretary of State Antony Blinken arrived in Shanghai for a visit aimed at improving U.S.-China relations, despite a host of unresolved issues.
What Happened: Blinken&#8217;s visit includes meetings with business leaders in Shanghai before heading to Beijing for discussions with Foreign Minister Wang Yi and possibly President Xi Jinping on Friday.
This trip is the latest in a series of high-level contacts and working groups that have somewhat eased the public acrimony that pushed relations to historic lows in early 2023.
However, the U.S. and China have made little progress on several contentious issues, including China&#8217;s supply of <a href="https://www.benzinga.com/news/24/04/38287054/97-of-all-illicit-fentanyl-that-arrives-in-the-us-comes-from-china-democratic-congressman-sounds-ala">chemicals for fentanyl production</a>, the Taiwan situation, and China&#8217;s support for Russia in the Ukraine war.
While significant progress is unlikely, both nations desire &#8220;open lines of communication to avoid awkward scenarios,&#8221; says Alfred Wu, an associate professor at the Lee Kuan Yew School of Public Policy in Singapore.
Blinken is expected to urge China to prevent its firms from aiding Russia&#8217;s defense industrial base. The U.S. has warned that Chinese companies are supplying dual-use technology that aids Russia&#8217;s war efforts.
See Also: <a href="https://www.benzinga.com/news/24/04/38349825/trumps-voters-enamored-with-robert-kennedy-jr-not-bidens-shows-latest-poll?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Trump&#8217;s Voters Enamored With Robert Kennedy Jr, Not Biden&#8217;s, Shows Latest Poll</a>
Despite these tensions, a Chinese foreign ministry official quoted by Xinhua said relations have shown signs of stabilization since the meeting between Biden and Xi in November 2023.
Other contentious issues on the agenda include the U.S. Congress&#8217;s <a href="https://www.benzinga.com/news/24/04/38348328/tiktok-sale-or-ban-social-media-giants-future-hangs-in-balance-as-house-passes-controversial-bill">move to force ByteDance to sell TikTok </a>or face a ban, and human rights concerns, particularly China&#8217;s treatment of Muslims in Xinjiang.
Despite the tensions, there have been attempts to find common ground on issues such as the Middle East conflict, demonstrating the potential for cooperation between the two nations.
Why It Matters: Before his visit, Blinken had <a href="https://www.benzinga.com/news/24/04/38351809/antony-blinken-to-warn-china-over-support-for-russias-military-during-upcoming-visit">expressed intentions to warn China </a>over its support for Russia&#8217;s military. He stated that the U.S. is prepared to take necessary steps against firms that undermine security in Ukraine and Europe.
In a G7 meeting, Blinken had also <a href="https://www.benzinga.com/markets/asia/24/04/38380008/us-mulls-sanctions-on-beijing-banks-for-alleged-role-in-putins-war-in-ukraine-china-cant-have-it-bot">hinted at the possibility of sanctions</a> on Chinese banks for their alleged support of Russia&#8217;s war in Ukraine.
Amid these tensions, the U.S. has been working on strengthening its own alliances. The AUKUS pact, a <a href="https://www.benzinga.com/news/24/04/38382368/antony-blinkens-top-deputy-dismisses-nuclear-arms-race-fears-amid-pact-with-australia-uk">trilateral defense and security agreement</a> between Australia, the U.K., and the U.S., is one such initiative aimed at enhancing stability in the Indo-Pacific region.
Read Next: <a href="https://www.benzinga.com/news/24/04/38348277/trump-vs-biden-nationwide-poll-shows-key-issue-decidedly-tilts-equation-in-favor-of-one-candidate?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Trump vs. Biden: Nationwide Poll Shows Key Issue Decidedly Tilts Equation In Favor Of One Candidate</a>
Photo by Alexandros Michailidis on Shutterstock
<div style="font-family: 'Lato', sans-serif">
<div>
<hr style="border: 0;height: 5px;background: #225aa9" />
<div style="background-color: #f5f5f5;background-position: center;background-size: cover;justify-content: center"></div>

 Engineered by Benzinga Neuro, Edited by 
 <a href="https://www.benzinga.com/topic/Pooja-Rajkumari" target="_blank" rel="noopener" style="color: #225aa9;text-decoration: none">Pooja Rajkumari</a> 
 
 
<hr style="border: 0;height: 1px;background: #225aa9" />

 The GPT-4-based Benzinga Neuro content generation system exploits the extensive Benzinga Ecosystem, including native data, APIs, and more to create comprehensive and timely stories for you. 
 <a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noopener" style="color: #225aa9;text-decoration: none">Learn more.</a>
 
<hr style="border: 0;height: 5px;background: #225aa9" />
 </div>
</div>

Politics

Antony Blinken Presses China On Russia Ties During Visit To Shanghai: Expert Says Visit Aims To 'Avoid Awkward Scenarios'

Goldman Sachs analyst Alexander Blostein maintains Invesco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IVZ#NYSE">IVZ</a>) with a Neutral and lowers the price target from $17.75 to $16.75.

Goldman Sachs Maintains Neutral on Invesco, Lowers Price Target to $16.75

<a href="https://www.qualcomm.com/news/releases/2024/04/qualcomm-continues-to-disrupt-the-pc-industry-with-the-addition-">https://www.qualcomm.com/news/releases/2024/04/qualcomm-continues-to-disrupt-the-pc-industry-with-the-addition-</a>
&nbsp;

QCOM

'Qualcomm Continues To Disrupt The PC Industry With The Addition Of Snapdragon X Plus Platform'

Goldman Sachs analyst Noah Poponak maintains GE Aero (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GE#NYSE">GE</a>) with a Buy and raises the price target from $190 to $211.

Goldman Sachs Maintains Buy on GE Aero, Raises Price Target to $211

Moderna Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) shares are trading higher Wednesday after the company announced an <a href="https://www.benzinga.com/pressreleases/24/04/ac38402918/moderna-and-openai-collaborate-to-advance-mrna-medicine">ongoing collaboration with OpenAI</a>.
What To Know: Moderna said the company and Microsoft Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>)-backed OpenAI share a vision of AI&#8217;s transformative potential in the future of business and healthcare.
Moderna began a collaboration with OpenAI in early 2023 with the launch of Moderna&#8217;s own instance of ChatGPT, called mChat. The company announced Wednesday that it has reached more than 80% internal adoption of mChat, which has accelerated the AI culture at Moderna.
As a result of the company&#8217;s <a href="https://www.benzinga.com/topic/ai">AI </a>integration, Moderna has deployed ChatGPT Enterprise and its enhanced capabilities such as Advanced Analytics, Image Generation and GPTs, which are now embedded across Moderna&#8217;s business functions as purpose-built assistants working alongside Moderna employees.
&#8220;Just as the introduction of the personal computer in the 1980&#8217;s changed the way we work and live, AI is on a path to completely transform our everyday lives &#8211; and OpenAI is helping to lead the way. Both our companies have shared values and are research-driven organizations pushing the boundaries of technology to drive transformation,&#8221; said Stéphane Bancel, CEO of Moderna. 
&#8220;Moderna has an ambitious plan to launch multiple products over the next few years, and collaborations with companies like OpenAI are critical to our ability to scale and maximize our impact on patients.&#8221;
Since adopting ChatGPT in recent months, Moderna said it has deployed more than 750 GPTs that have helped drive automation and productivity. 
Moderna is set to report financial results for the first quarter on May 2. The company is expected to report a loss of $3.68 per share and revenue of $97.501 million, according to estimates from <a href="http://pro.benzinga.com">Benzinga Pro</a>.
See Also: <a href="https://www.benzinga.com/markets/equities/24/04/38369584/boeing-foresees-slower-787-production-ramp-up-due-to-supplier-shortages-report">Boeing Foresees Slower 787 Production Ramp-Up Due To Supplier Shortages: Report </a>
MRNA Price Action: <a href="https://www.benzinga.com/quote/MRNA">Moderna shares</a> were up 3.9% at $112.10 at the time of publication, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Lutsenko_Oleksandr from Shutterstock.

MRNA

MSFT

Moderna Stock Jumps On Collaboration With OpenAI: What's Going On?

<a href="https://www.digitimes.com/news/a20240424PD207/hbm-price-market-competition-samsung-sk-hynix-tsmc.html?chid=10" title="https://www.digitimes.com/news/a20240424PD207/hbm-price-market-competition-samsung-sk-hynix-tsmc.html?chid=10">https://www.digitimes.com/news/a20240424PD207/hbm-price-market-competition-samsung-sk-hynix-tsmc.html?chid=10</a>

SSNLF

'HBM Prices Likely To Fall In 2H24 Due To Intensified Market Competition' - DigiTimes

Keybanc analyst Thomas Blakey initiates coverage on Super Micro Computer (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) with a Sector Weight rating.

SMCI

Keybanc Initiates Coverage On Super Micro Computer with Sector Weight Rating

WIIM

RBBN

Ribbon Communications shares are trading higher after the company reported Q1 financial results and issued guidance.

Bunge Limited&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BG#NYSE">BG</a>) shares traded lower&nbsp;&nbsp;Wednesday after the company<a target="_blank" href="https://www.benzinga.com/premarket" rel="noreferrer noopener">&nbsp;reported first-quarter results</a>.
The company reported adjusted earnings per share of $3.04,&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/04/b38398262/bunge-reports-first-quarter-2024-results" rel="noreferrer noopener">beating the analyst consensus of $2.54</a>.&nbsp;
Quarterly revenues of $13.417 billion<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">&nbsp;missed the street view of $13.956 billion.</a>
In the agribusiness, higher processing results were more than offset by lower results in merchandising, while refined and specialty Oil units were down from a strong prior year.&nbsp;
&#8220;During the quarter we invested further in our pipeline of growth projects and made excellent progress&nbsp;on&nbsp;integration planning for our announced combination with Viterra,&#8221; said Greg Heckman, Bunge&#8217;s&nbsp;Chief Executive Officer.
Bunge exited the quarter with cash and equivalents worth $2.939&nbsp;billion&nbsp;and inventories worth $7.505 billion.
According to&nbsp;<a target="_blank" href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw" rel="noreferrer noopener">Benzinga Pro</a>,&nbsp;BG stock has gained over 15% in the past year.&nbsp;Investors can gain exposure to the stock via&nbsp;First Trust Cons. Staples AlphaDEX&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FXG#NYSE">FXG</a>) and&nbsp;VanEck Agribusiness ETF&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOO#NYSE">MOO</a>).
Outlook:&nbsp;Bunge reiterated a full-year 2024 adjusted&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">EPS outlook of approximately $9.00 versus&nbsp;the $9.39 estimate.</a>
The company sees full-year 2024 net interest expense in the range of $280 million to $310 million, which is down from previous&nbsp;expectation&nbsp;of $300 million to $330 million.
&#8220;While we are off to a strong start, we continue to have limited visibility into the back half of the year,&#8221; Heckman added.
Price Action:  BG shares are trading lower by 5.57% to $103.51 at last check Wednesday.

Earnings

Markets

Bunge Shares Dip Over 5% After Q1 Results: Details Here

Lake Street analyst Ben Klieve maintains Vital Farms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VITL#NASDAQ">VITL</a>) with a Buy and raises the price target from $26 to $32.

VITL

Lake Street Maintains Buy on Vital Farms, Raises Price Target to $32

Visa CFO Says Overall, Consumer Trends Continued To Be Remarkably Resilient; Travel Volumes Remain Under 2019 Levels In China; Chinese Consumer Under Pressure Due To Macroeconomic Trends; Visa Saw 2q Volume Payments Growth Everywhere, Except For Asia-pacific Market

Loop Capital analyst Alan Gould maintains Spotify Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>) with a Hold and raises the price target from $250 to $300.

SPOT

Loop Capital Maintains Hold on Spotify Technology, Raises Price Target to $300

Sector Insights: What Could Go Right In 2024?

How I Construct My Dividend Growth-Focused Roth IRA Portfolio

Tech Was Best In Q4 Earnings But Look To The Rest As Market Broadens

Taking Stock: Q2 2024 Equity Market Outlook

First Trust NASDAQ Technology Dividend Index Fund ETF declares $0.1907 dividend

Equity Outlook: Earnings Step Back Into The Market Spotlight

April 2024 Perspective

TDIV: Technology With A Dividend Spin

Tailwinds In Tech

Adapting To Economic Paradigm Shifts

ACES

ACTV

ACWI

ACWV

AFMC

AFSM

AFTY

AGGY

AGNG

ANEW

ARKF

ARKG

ARKK

ARKQ

ARKW

ARKX

ASET

ASHR

ASHS

AVIG

AVUV

BAPR

BATT

BBAG

BBEU

BBJP

BBMC

BFOR

BKAG

BKMC

BLCN

BLES

BLOK

BMED

BMVP

BNDC

BOIL

BOND

BOTZ

BOUT

BTEC

BTEK

BUYZ

BYLD

BYOB

CBON

CHIM

CHIQ

CHIR

CHIU

CHIX

CHRG

CIBR

CLNR

CLOU

CMBS

CNCR

CNRG

CNXT

CNYA

CQQQ

CRBN

CTEC

CXSE

DAPP

DBEU

DBEZ

DBJP

DDIV

DEUS

DGRO

DGRW

DIVS

DRIV

DTEC

DVLU

DWLD

DXJS

EAGG

ECNS

EDOC

EQAL

ERTH

ESGB

ESGG

ESPO

ETHO

EUDG

EUDV

EURL

EUSB

EUSC

EWJV

FBND

FCOM

FDRV

FEUZ

FFIU

FFTY

FHLC

FIBR

FIGB

FINX

FITE

FIVG

FIXD

FLCB

FLCH

FLEE

FLEU

FLGV

FLHK

FLJH

FLJP

FLQM

FLTW

FNDB

FNDX

FNGS

FORH

FOVL

FPXE

FRTY

FSEC

FSMD

FTDS

FTEC